This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the lifesciences and healthcare sector. However, they are vital to the drugdevelopment and approval process and critical in enabling access to innovative medicines.
That is the opinion of Ron Emerson, RN, global healthcare lead at Zoom, as he looks ahead at what he believes will be some developments in healthcare in 2022. You predict that decentralization will become a major theme for health and lifescience organizations. Please elaborate.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and lifesciences firms, and insurance companies serve patients as end users. Stacy regularly advises on how COVID innovations such as telehealth need to remain as permanent options to enhance patient care. Connect with her at [link].
Jane Reed, Director of LifeSciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety. Discussions will focus on the nuanced packaging and delivery requirements for MABs, emphasizing the commitment to safety standards while ensuring the drugs’ effectiveness.
Companies with niche technologies or expertise: Startups with unique solutions in specific areas like AI-powered diagnostics, remote patient monitoring, or telehealth platforms. Pharmaceutical and LifeSciences Companies: These companies are looking for HealthTech solutions to: Enhance clinical trials and drugdevelopment processes.
Precision medicine will continue to evolve in 2024: In disease areas like oncology, we will start to see AI playing a larger role in target discovery and biomarker or patient subpopulation identification, the cornerstones to early precision drugdevelopment.
Blockchain technology’s potential impact on the lifesciences industry (drugdevelopment, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content